Strategic Workshops Supporting Pharma’s Future
How to deliver the degree of holistic and objective understanding that today’s market demands
For any company seeking success, strategic intelligence is crucial.
For the pharma industry, the questions surrounding how to win have become increasingly complex, and the answers even more so. Distilling and prioritising the information crucial to strategy-formation can appear a labrynthine task.
So how do you deliver the degree of holistic – and objective – understanding that today’s circuitous market demands? Should you challenge your existing business model? And how can you prepare for the next disruption?
Breakthrough thinking, we’ve seen, lies in the prioritization of a full Strategic Preparedness Workshop (SPW). The SPW goes far beyond traditional pharma workshops that assess one or a few competitors or helps to clarify the path to an already clear-cut goal. Instead, SPWs align key stakeholders early in the direction setting process via a thorough exploration of the strategic challenges, disruptors, and opportunities facing a company. SPWs give leaders a chance to align, engage, and explore the best strategic approach based on deep knowledge of external as well as internal success factors.
In this paper, we’ll show how SPWs should be run – and why.
You may also be interested in…
Deallus sponsoring and speaking at the Pharma CI EU Conference
We are excited to be sponsoring and speaking at the Pharma CI EU conference, held in Rome on 30-31 March 2023. Julie Munch Khan, COO, and Stephen Small, Senior Principal at Deallus will be joining other Competitive Intelligence experts across Pharma, Biotech and Medical Devices.
Overview of current policy for rare disease in China
For the first time after decades of negligence in this area, China published the First List of Rare Diseases (FLRDs). This was a key step in improving and standardising the regulatory system of rare disease management, orphan drug development, and review and approval.
Post-ASCO 2022: Summary of key breast cancer highlights
With the conclusion of another ASCO, we were presented with exciting new breakthrough data of Antibody Drug Conjugates in breast cancer. Enhertu (trastuzumab deruxtecan) demonstrated significant benefit in the treatment of a new subtype of breast cancer, HR+/ /HER2-low.